During severe inflammatory coronavirus infectious disease (CoVID-19) pandemic and based on evidence on COVID-19 epidemiology, patients with primary cutaneous lymphomas (PCLs) have risk for developing complicated COVID-19 infections in consideration of their older age (majority above 60) and their potential underlying predisposing conditions (e.g. hypertension, diabetes).1,2,3 Moreover, PCL patients with aggressive biologic behavior should be carefully monitored according to guidelines for patients with neoplastic disease.